UCSF launches executive course in
* WHAT:
The Department of Biopharmaceutical Sciences (DBS) and Center for Drug Development Science (CDDS) of the UCSF School of Pharmacy are co-hosting a lecture and reception with the Swiss Embassy to celebrate the launch of the American Course on Drug Development and Regulatory Sciences (ACDRS). The two-year postgraduate course will provide scientific leaders and policy makers in academia, industry and government the background and connections needed to modernize US drug development and regulatory processes and make safer, more effective and more affordable medical products available to the public. Lectures and discussion will focus on the principles and processes of optimal drug development, facilitative regulation and the significance for the United States of current European regulation initiatives. Attendees will include international leaders in science, industry and government.
* WHEN:
Monday, September 10, 6:15 p.m. to 9:00 p.m.
* WHERE:
Embassy of Switzerland, 2900 Cathedral Ave., NW, Washington, DC.
* INTERVIEW & PHOTO OPPORTUNITIES:
Consular corps, senior scientists and regulatory officials, as well as the following program leaders:
Ellen G. Feigal, MD, ACDRS director and adjunct professor, UCSF School of Pharmacy
Carl C. Peck, MD, founder and former director, CDDS, and adjunct professor, UCSF School of Pharmacy
Fritz R. Buhler, MD, director, European Course in Pharmaceutical Medicine and professor of Pharmaceutical Medicine, University Hospital, Basel, Switzerland
Charles Grudzinskas, PhD, managing director, NDA Partners LLC
* RSVP REQUIRED:
Please contact ACDRS Program Manager Jaime Kenyon, MPH, at (602) 319-5831 or [email protected]
* DETAILS:
The ACDRS is based upon the existing European Course of Pharmaceutical Medicine at the University of Basel, Switzerland. The first program of this kind in the United States, ACDRS was developed by the DBS and CDDS, both of the UCSF School of Pharmacy, in conjunction with the FDA, professional societies, a network of universities, pharmaceutical, biotechnology and device companies, and with the European Course in Pharmaceutical Medicine. It was established with funding from the Stuart Beal and Lewis Sheiner Fund of the UCSF School of Pharmacy. The course aims to prepare current and future biopharmaceutical leaders to lead innovative changes in drug development and regulatory practices that utilize novel and best solutions to optimize translation of drug discoveries into life-saving medical products.
* ABOUT UCSF:
UCSF is a leading university that advances health worldwide by conducting advanced biomedical research, educating graduate students in the life sciences and health professions, and providing complex patient care.